Mounjaro (tirzepatide), a weight-loss and diabetes medication by Eli Lilly, experienced a significant sales decline in March, posting total sales of ₹114 crore, down from ₹135 crore in February. This downturn is attributed to aggressive price cuts by Novo Nordisk on its competing drugs, Ozempic and Wegovy (semaglutide), as well as the entry of low-cost generics. The sales of semaglutide increased to ₹59 crore in March from ₹48 crore in February, reflecting a growing preference for more affordable options. Eli Lilly's India head, Winselow Tucker, stated that there are currently no generics for tirzepatide, and he ruled out immediate price cuts to regain market share. Despite the competition, Tucker remains confident in the unique benefits of tirzepatide, which is the only dual GIP/GLP-1 receptor agonist approved for treating type-2 diabetes and chronic weight management. Analysts suggest that semaglutide could capture a significant portion of the market within the next 12-14 months, potentially leading to 80% of weight loss patients using semaglutide, while Mounjaro retains 20%.